非小细胞肺癌XRCC1Arg399Gln基因分析与顺铂疗效的关系

Association between XRCC1 Arg399 Gln Polymorphisms in Non-small Cell Lung Cancer with Efficacy of Platinum-based Chemotherapy

目的探讨X线修复交叉互补基因1(x-ray repair cross complementing group 1,XRCC1)Arg399Gln基因多态性分析与顺铂疗效的相关性.方法回顾性分析83例接受以顺铂为主的联合化疗非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的治疗效果.应用多聚酶链反应-限制性片段长度(polymerase chainreactionrestriction fragment length polymorphism,PCR-RFLP)法分析XRCC1Arg399Gln的多态性,并对两者关系进行分析.结果携带XRCC1399Arg/Arg基因型患者49例(59.04%),携带Arg/Gln基因型28例(33.73%),携带Gln/Gln基因型6例(7.23%).在XRCC1399Arg/Arg、Arg/Gln和Gln/Gln携带者中,化疗有效率分别为42.86%、11.2%和19.3%.A/A组化疗有效率优于A/G+G/G(42.86%vs11.76%),P<0.05.Gln等位基因携带者的疗效不如Arg等位基因携带者.XRCC1基因型与化疗毒副反应的发生没有明显相关性.结论 XRCC1Arg399Gln基因分型与顺铂疗效有一定关系,其中携带XRCC1399Arg/Arg患者更有利于使用顺铂,可以为临床用药提供一定的依据.

Objective To investigate the relationship between XRCC1 Arg399 Gin polymorphisms and the efficacy of platinum-based chemotherapy in non-small cell lung cancer （NSCLC） Methods Eighty-three patients with NSCLC treated with platinum-based chemotherapy were enrolled in this study and their tumor samples were collected retrospectively for analysis. The polymorphisms of XRCCI Arg399 Gln in NSCLC were detected by polymerase chain reaction-restriction fragment length polymorphism （PCR-RFLP） , and the data were collected and analyzed. Results Of all cases, the frequencies of XRCC1 codon 399 Arg/Arg, Arg/Gln and Gln/Gln genotype were 59.04%, 33.73% and 7.23%, respectively. The response rate to therapy in patients with XRCC1 codon 399 Arg/Arg genotype （42.86%） was significantly higher than that in patients with the Arg/Gln and Gln/Gln genotype （11.76%） . The response rate to therapy in patients with XRCC1 codon 399 Arg/Arg genotypes was significantly higher than that in patients with other XRCC1 genotypes. XRCC1 genotypes had no significant correlation with the side effects of chemotherapy. Conclusion It has certain relationships between the polymorphisms of XRCC 1 Arg399 Gin and platinum-based chemotherapy in NSCLC, and the patients with XRCC1 399Arg/Arg are more conducive to use platinum-based chemotherapy. The results can provide some basis for clinical medication.